Cited by 502Sepsis Diagnosis and TreatmentAntibiotics Pharmacokinetics and EfficacyAcute Kidney Injury Research

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Open access

Dellinger, R. Phillip, Bagshaw, Sean M., Antonelli, Massimo, Foster, Debra M., Klein, David J., Marshall, John C., Palevsky, Paul M., Weisberg, Lawrence S., Schorr, Christa A., Trzeciak, Stephen, Walker, Paul M., for the EUPHRATES Trial Investigators·2018·JAMA

DOI 10.1001/jama.2018.14618PMC PMC6233793

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P = .49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P = .92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2018.14618

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Self-citation
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,371
Self-citation
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,869
Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock
Cruz, D. N., Antonelli, M. M., Fumagalli, R., Foltran, F., Brienza, N., Donati, A., Malcangi, V., Petrini, F., Volta, G., Pallavicini, F. M. B., et al. (2009) · JAMA · doi:10.1001/jama.2009.856 · Cited by 841
Self-citation
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis: The ACCESS Randomized Trial
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.2194 · Cited by 812
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
Opal, S. M., Scannon, P. J., Vincent, J., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999) · The Journal of Infectious Diseases · doi:10.1086/315093 · Cited by 609
Surviving Sepsis Campaign
Levy, M. M., Rhodes, A., Phillips, G. S., Townsend, S. R., Schorr, C., Beale, R. J., Osborn, T. M., Lemeshow, S. A., Chiche, J., Artigas, A., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000723 · Cited by 583
Self-citation
Treatment of Septic Shock with Human Monoclonal Antibody HA-1A
McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., Smith, C. R., & and CHESS Trial Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-1-199407010-00001 · Cited by 492
Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial
The ABDOMIX Group, Payen, D. M., Guilhot, J., Launey, Y., Lukaszewicz, A. C., Kaaki, M., Veber, B., Pottecher, J., Joannès-Boyau, O., Martin‐Lefèvre, L., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3751-z · Cited by 418
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial
Levin, M., Quint, P. A., Goldstein, B., Barton, P., Bradley, J. S., Shemie, S., Yeh, T. S., Kim, S. S., Cafaro, D. P., Scannon, P. J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02712-4 · Cited by 408

Flagged first, then by citations

Show all 25 references

2 of the 25 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 501

Treatment of sepsis-induced acute kidney injury in the ICU: the therapeutic targets do not seem to be established yet
Quenot, J., Dargent, A., Large, A., Roudaut, J.-B., Andreu, P., & Barbar, S. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.66 · Cited by 8
Blood Purification in Patients with Sepsis Associated with Acute Kidney Injury: A Narrative Review
Kamei, J., Kanamoto, M., Igarashi, Y., Suzuki, K., Fujita, K., Kuwana, T., Ogura, T., Mochizuki, K., Banshotani, Y., Ishikura, H., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196388 · Cited by 10
Autologous cryo-shocked neutrophils enable targeted therapy of sepsis via broad-spectrum neutralization of pro-inflammatory cytokines and endotoxins
Gao, Q., Yan, Y., Zhang, J., Li, X., Wang, J., Feng, Y., Li, P., Wang, H., Zhang, Y., He, L., et al. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1359946 · Cited by 9
Comparing adsorptive blood purification modalities for sepsis patients: A systematic review and network meta-analysis
Xing, H., Wei, Y., Zhang, D., Jiang, Z., Qin, J., Ou, S., & Wu, W. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.107994 · Cited by 10
Targeted Rapid Endotoxin Adsorption: Can We Bring Precision Medicine to Sepsis?
Kellum, J. A., Kamaluddin, E., & Foster, D. (2025) · Blood Purification · doi:10.1159/000544989 · Cited by 9
Self-citation
Recent advances in membrane and sorbent design for blood purification in sepsis and septic shock
Ding, X., Zhou, X. Q., & Du, B. (2025) · Chem · doi:10.1016/j.chempr.2025.102529 · Cited by 9
Non-antibiotic therapies for sepsis: an update
Vincent, J., & Mongkolpun, W. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1581606 · Cited by 9
New biomarkers for respiratory infections
Póvoa, P. M. S. R., Coelho, L., & Bos, L. D. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000669 · Cited by 9
LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients
Dargent, A., de Barros, J.-P. P., Saheb, S., Bittar, R., Goff, W. L., Carrié, A., Gautier, T., Fournel, I., Rérole, A. L., Choubley, H., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120001132 · Cited by 9
Adjunctive Immunotherapy With Polyclonal Ig-M Enriched Immunoglobulins for Septic Shock: From Bench to Bedside. The Rationale for a Personalized Treatment Protocol
Busani, S., Roat, E., Tosi, M., Biagioni, E., Coloretti, I., Meschiari, M., Gelmini, R., Brugioni, L., Biasi, S. D., & Girardis, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.616511 · Cited by 9
Sepsis 2021: a review
Wentowski, C. C., Inglés, D. P., & Nielsen, N. D. (2021) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2021.10.001 · Cited by 11
Should endotoxin be a research priority in Gram-negative sepsis and septic shock?
Mallat, J., Leone, S., Cascella, M., & Fiore, M. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1627871 · Cited by 9
Alternative Approaches to Counter Multidrug-Resistant Bacterial Pathogens
Saxena, D., Maitra, R., Dasgupta, A., & Chopra, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5272-0_5 · Cited by 8
Immunomodulation in Pediatric Sepsis: A Narrative Review
Bottari, G., Taccone, F. S., Corrias, A., Irrera, M., Currao, P., Salvagno, M., Cecchetti, C., & Payen, D. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092983 · Cited by 10
The effects of extracorporeal blood purification (oXiris®) in patients with cardiogenic shock who require VA-ECMO (CLEAN ECMO): a prospective, open-label, randomized controlled pilot study
Ko, R., Choi, K. H., Lee, K., Jeon, J., Jang, H., Chung, C., Cho, Y. H., Park, T., Lee, J., Song, Y.-B., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05495-4 · Cited by 9
Extracorporeal Blood Purification in Burns: For Whom, Why, and How?
Abraham, P. S., Monard, C., Schneider, A. G., & Rimmele, T. R. (2022) · Blood Purification · doi:10.1159/000525085 · Cited by 8
Epidemiology of sepsis in a Japanese administrative database
Imaeda, T., Oami, T., Takahashi, N., Saito, D., Higashi, A., & Nakada, T. (2023) · Acute Medicine & Surgery · doi:10.1002/ams2.890 · Cited by 6
Peritoneal sepsis caused by Escherichia coli triggers brainstem inflammation and alters the function of sympatho-respiratory control circuits
Kola, G., Clifford, C., Campanaro, C., Dhingra, R. R., Dutschmann, M., Jacono, F. J., & Dick, T. E. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03025-7 · Cited by 8
Clinical and Economic Evaluation of the Blood Purification with Selective Sorption Techniques in ICU Patients
Polushin, Y. S., Соколов, Д. В., Dreval, R. О., & Zabotina, A. N. (2023) · Messenger of Anesthesiology and Resuscitation · doi:10.24884/2078-5658-2023-20-1-6-16 · Cited by 8
Measuring organ dysfunction
Marshall, J. C. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00660-9 · Cited by 8
Self-citation
Pathophysiology of anaemia.
Campbell, K. (2004) · PubMed · Cited by 8
Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy?
Pickkers, P., & Russell, J. A. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5481-5 · Cited by 8
Simultaneous removal of endotoxins, inflammatory mediators and uremic toxins in ICU patients with septic shock: a retrospective cohort study
Theisen, B. E., Lichtenstern, C., Nußhag, C., Tan, B., Hölle, T., Weigand, M. A., Kalenka, A., & Fiedler-Kalenka, M. O. (2024) · Scientific Reports · doi:10.1038/s41598-024-70522-3 · Cited by 8
Effects on mortality of blood purification techniques in severe septic shock patients. An updated Bayesian network meta-analysis of randomized controlled trials
Meco, M., Agosteo, E., Zulli, P., Nisi, F., & Giustiniano, E. (2025) · Journal of Critical Care · doi:10.1016/j.jcrc.2025.155330 · Cited by 7
Unique Dual‐Affinity Strategy for Specific Lipopolysaccharide Clearance in Sepsis Therapy: Peptide‐Conjugated Molecularly Imprinted Polymers via Emulsion Interfacial Polymerization
Wei, H., Li, X., Xiong, Y., Zhang, X., Li, M., Zhang, H., Chen, X., Wang, D., Qin, H., Chang, Y., et al. (2025) · Advanced Materials · doi:10.1002/adma.202517135 · Cited by 7
TA-Zr/Ce Nanozyme-Mediated Lipopolysaccharide Dephosphorylation: A Targeted Strategy for Sepsis Treatment with Hemoperfusion Applications
Zhao, X., Shao, R., Yu, Y., Hu, Z., Jiang, Y., Zhou, Y., Zhong, Z., & Zhou, J. (2026) · ACS Nano · doi:10.1021/acsnano.5c21151 · Cited by 7
Dynamics of organ dysfunction and inflammation markers in patients with septic shock during multimodal hemocorrection: a multicenter, randomized, controlled study
Rey, S. I., Кулабухов, В. В., Popov, A. Y., Никитина, О. В., Анатольевич, Б. Г., Kim, T. G., Викторович, М. С., Магомедов, М. А., Игнатенко, О. В., Кротенко, Н. П., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-60-71 · Cited by 7
Microbial cell factories using Paenibacillus : status and perspectives
Yuan, P., Chen, Z., Xu, M., Cai, W., Liu, Z.-Z., & Sun, D. (2023) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2023.2289342 · Cited by 7
Recent advances in blood toxin removal technology
Wang, L., Han, K., Jiang, X., Mao, C., Li, X., & Zhou, M. (2024) · Sustainable materials and technologies · doi:10.1016/j.susmat.2024.e00828 · Cited by 7
Effects of Early Initiation of Polymyxin B Hemoperfusion Therapy in Patients with Cancer with Refractory Septic Shock
Lee, J. H., Han, W. H., Kim, D. H., & Kim, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041009 · Cited by 7
Does Continuous Renal Replacement Therapy with oXiris in Septic Shock Have Any Positive Impact? Single-Centre Experience with oXiris Therapy in Septic Shock Patients
Mielnicki, W., Dyla, A., Zając, M., Rokicka-Demitraszek, N., & Smereka, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247527 · Cited by 7
Extrakorporale Behandlungsstrategien der Sepsis: die Rolle der Plasmapherese
Stahl, K., Bode, C., & David, S. (2021) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-1105-0572 · Cited by 7
Blood filters in children with COVID ‐19 and acute kidney injury: A review
Raina, R., Sethi, S. K., Chakraborty, R., Singh, S., Teo, S., Khooblall, A., Montini, G., Bunchman, T. E., Topaloğlu, R., & Yap, H. K. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13793 · Cited by 7
Mortality Risk Prediction in Abdominal Septic Shock Treated with Polymyxin-B Hemoperfusion: A Retrospective Cohort Study
García-Ramos, S., Caamaño, E., Benítez, P. R., Benito, P., Calvo, A., Ramos, S., Power, M., Garutti, I., & Piñeiro, P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071023 · Cited by 7
Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study
Mochizuki, K., Mori, K., Kamijo, H., Ichikawa, M., Nitta, K., & Imamura, H. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00674-8 · Cited by 7
Lesión renal aguda en COVID-19: puesta al día y revisión de la literatura
Vargas, J. G., Avila, N., Hurtado, D., Cárdenas-Roldán, J., Peña, D. J. S., & Ortíz, G. (2020) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2020.10.004 · Cited by 7
Detection of 20 respiratory viruses and bacteria by influenza-like illness surveillance in Beijing, China, 2016–2018
Liang, H., HaiBin, W., & Lili, R. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.11.014 · Cited by 7
Which Patient Phenotype Is the Ideal Candidate for Hemoadsorption in Acute and Chronic Kidney Disease?
Ronco, C., & Kellum, J. A. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-24-00001 · Cited by 7
Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection
Xia, G., Xu, X., You, X. B., Wang, X., Feng, D. D., Lei, S., & Jiang, R. L. (2023) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-023-00647-2 · Cited by 6
Charge-Engineered LPS-Targeting Magnetic Nano-adsorbents with Optimized Harvesting Strategy Advance Sepsis Blood Purification Nanotherapeutic
Liu, X., Cheng, S., Yang, X., Wang, Y., Chen, S., Ling, Z., Xiao, Y., Zhao, W., & Zhao, C. (2025) · Research · doi:10.34133/research.0991 · Cited by 6
Rare case of COVID-19 presenting as acute abdomen and sepsis
Alharthy, A., Balhamar, A., Faqihi, F., Nasim, N., Noor, A. S. N., Alqahtani, S. A., Memish, Z. A., & Karakitsos, D. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100818 · Cited by 6
Advancements in the pharmacological management of sepsis in the elderly
Psarrakis, C., & Giamarellos‐Bourboulis, E. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213828 · Cited by 9
Clinical implications of endotoxin activity and Polymyxin‐B hemoperfusion in critically ill patients with septic cardiomyopathy: A single‐center, retrospective, observational study
Cutuli, S. L., Carelli, S., Cascarano, L., Cicconi, S., Silvestri, D., Cicetti, M., Vallecoccia, M. S., Pintaudi, G., Tanzarella, E. S., Grieco, D. L., et al. (2023) · Artificial Organs · doi:10.1111/aor.14645 · Cited by 6
Self-citation
The clinical efficacy and suitable implementation of two extracorporeal blood purification therapies: AN69-oXiris versus PMX-HP
Kim, H. S., Chung, Y. J., Lee, G. R., & Kim, E. Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1344893 · Cited by 6
Effects of Oxiris® Therapy on Cytokine Elimination after a LPS Infusion—An Experimental Animal Study
Kalenka, A., Arens, P., Müllenbach, R., Weigand, M. A., Brune, M., & Fiedler, M. O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179283 · Cited by 6
Terapias de purificación sanguínea en COVID-19
Daza-Arnedo, R., Aroca, G., Rico-Fontalvo, J. E., Vela, E. R., Pájaro-Galvis, N., Montiel, L. G. S., Robles, M. C. M., Calvo, C. P., Portela-Buelvas, K., & Portela-Buelvas, K. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.supl.2.476 · Cited by 6
Endotoxemic Sepsis: Clinical Features and Therapy
Kellum, J. A., Shoji, H., Foster, D., & Walker, P. M. (2022) · Journal of Translational Critical Care Medicine · doi:10.4103/jtccm-d-22-00015 · Cited by 6
Self-citation
Therapeutic apheresis in sepsis
Klinkmann, G., Altrichter, J., Reuter, D. A., & Mitzner, S. R. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13815 · Cited by 6
CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury
Clark, E. G., Hiremath, S. S., Soroka, S., Wald, R., Weir, M. A., On behalf of the CSN COVID-19 Rapid Response Team, Antonsen, J. E., Banks, C. A., Clark, D. A., Copland, M. A., et al. (2020) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358120941679 · Cited by 6
Safety considerations of current drug treatment strategies for nosocomial pneumonia
Ceccato, A., Giannatale, P. D., Nogas, S., & Torres, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1857362 · Cited by 6
Preliminary study on the safety and efficacy of a new polymyxin B‐immoblized resin column in treatment of LPS‐induced sepsis beagles
Li, Y., Yang, Z., Hu, J., & Lin, Z. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12199 · Cited by 6
Effect of polymyxin B hemoperfusion on the outcome of patients with sepsis and septic shock
Lin, W., Lai, C., Wang, J., & Chao, C. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.11.013 · Cited by 6
Comment on Hu et al: The cytokine storm and COVID‐19
Faqihi, F. A., Alharthy, A. M., Memish, Z. A., & Karakitsos, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26396 · Cited by 6
Building an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report
Reddy, K., Aggarwal, N. R., Alipanah, N., Annane, D., Antcliffe, D. B., Babalis, D. S., Baillie, J. K., Beane, A., Bos, L. D. J., Burrell, A. J. C., et al. (2025) · Efficacy and Mechanism Evaluation · doi:10.3310/ttnd8896 · Cited by 6
Self-citation
Targeting lipopolysaccharides in gram-negative sepsis: therapeutic advances and challenges
AKELE, O., Rana, F., Acharya, S., LeDoux, D., & Chalhoub, M. N. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2546487 · Cited by 5
Real-World Outcomes and Prognostic Factors of Polymyxin B Hemoperfusion in Severe Sepsis and Septic Shock: A Seven-Year Single-Center Cohort Study from Taiwan
Chang, W.-H., Hu, T.-Y., & Kuo, L. (2025) · Life · doi:10.3390/life15081317 · Cited by 5
Impact of Continuous Renal Replacement Therapy on Outcomes in Septic Shock Patients Receiving Polymyxin B Hemoperfusion: A Retrospective Cohort Study
Chang, W.-H., Yang, S.-H., Shen, H.-F., Hu, T.-Y., & Wu, W.-J. (2025) · Biomedicines · doi:10.3390/biomedicines13122904 · Cited by 5
The molecular ICU: a primer on omics, informatics and the future of precision critical care
Nynatten, L. R. V., Raheel, H., Basmaji, J., Slessarev, M., & Fraser, D. D. (2026) · Critical Care · doi:10.1186/s13054-026-06169-5 · Cited by 5
Use of Therapeutic Apheresis methods in ICU
Zikou, X. T., Vaia, D., Vasiliki, P., Chlorokostas, P., & Aloizos, S. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103853 · Cited by 5
Evaluating the Therapeutic Efficiency and Efficacy of Blood Purification for Treating Severe Acute Pancreatitis: A Single-Center Data Based on Propensity Score Matching
Huang, H., Mo, J., Jiang, G.-Z., & Lu, Z. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s475186 · Cited by 5
Data-driven analysis that integrates bioinformatics and machine learning uncovers PANoptosis-related diagnostic genes in early pediatric septic shock
Wang, J., Chen, S., Chen, L., & Zhou, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37853 · Cited by 6
The polymyxin‐B direct hemoperfusion OPTimal Initiation timing with Catecholamine PMX ‐ OPTIC study: A multicenter retrospective observational study
Nakamura, K., Okazaki, T., Tampo, A., Mochizuki, K., Kanda, N., Ono, T., Yanagita, K., Shimomura, T., Murase, T., Saito, K., et al. (2024) · Artificial Organs · doi:10.1111/aor.14865 · Cited by 5
Application of the In Vitro HoxB8 Model System to Characterize the Contributions of Neutrophil–LPS Interaction to Periodontal Disease
Sochalska, M., Stańczyk, M. B., Użarowska, M., Zubrzycka, N., Kirschnek, S., Grabiec, A. M., Kantyka, T., & Potempa, J. (2020) · Pathogens · doi:10.3390/pathogens9070530 · Cited by 5
Uncertain Clinical Effect of Polymyxin B Hemoperfusion in Patients with Septic Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
Lee, J. M., Baek, S. D., Kim, T. H., Jeon, H. R., Han, J., & Chang, J. W. (2021) · Shock · doi:10.1097/shk.0000000000001752 · Cited by 5
The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP)
Kuwana, T., Kinoshita, K., Ihara, S., Sawada, N., Hosokawa, T., Mutoh, T., Iguchi, U., Nakagawa, K., & Yamaguchi, J. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s374920 · Cited by 5
Blood perfusion with polymyxin B immobilized columns in patients with COVID-19 requiring oxygen therapy
Katagiri, D., Tsukada, A., Izumi, S., Shimizu, Y., Terada-Hirashima, J., Uemura, Y., Kusaba, Y., Takasaki, J., Takoi, H., Tamura‐Nakano, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63330-2 · Cited by 5
Factors affecting the effectiveness and safety of polymyxin B in the treatment of Gram-negative bacterial infections: A meta-analysis of 96 articles
Zhao, Y., Wang, C.-Y., Liu, J.-Y., Li, J.-K., Liu, H.-Y., Sun, Z., Zhang, B.-K., & Yan, M. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107262 · Cited by 6
Time to administer polymyxin B hemoperfusion and hemodynamics in patients with septic shock requiring high-dose norepinephrine: a predetermined analysis of a prospective cohort study
Miyamoto, K., Kawazoe, Y., Miyagawa, N., Yamamura, H., Ohta, Y., Kimura, T., Toyoda, Y., Kyo, M., Sato, T., Kinjo, M., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05422-7 · Cited by 5
For safe and adequate blood purification therapy in severe COVID-19 ‒ what we have learned so far
Katagiri, D. (2022) · Global Health & Medicine · doi:10.35772/ghm.2022.01004 · Cited by 5
Prediction of septic shock outcome in children requiring extracorporeal hemocorrection
Аleksаndrovich, Y. S., Середняков, К. В., Rybyanov, V. V., & Pshenisnov, K. V. (2022) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology202206144 · Cited by 5
Blood purification in sepsis
Jörres, A. (2018) · Critical Care · doi:10.1186/s13054-018-2286-4 · Cited by 5
Technicalities, current evidence, and clinical indications of hemoadsorption in critically ill children
Ceschia, G., Longo, G., Igeño, J. C., & Vidal, E. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-06882-3 · Cited by 4
Does CytoSorb Interfere with Immunosuppression? A Pharmacokinetic and Functional Evaluation
Harm, S., Schildböck, C., Cont, D., Weber, V., & Hartmann, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111468 · Cited by 4
TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion
Iba, T., Helms, J., Nagaoka, I., Mineshima, M., & Ferrer, R. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00835-6 · Cited by 4
Use of Oxiris membrane in real-world clinical practice in critical care patients: a multicenter observational study
Villa, G., Fioccola, A., Cecchi, M., Calabrisotto, C. S., Montin, D. P., Rosa, S. D., Scoccia, G., Manno, A., Tofani, L., Santorsola, C., et al. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00305-3 · Cited by 4
Adsorptive Therapies in Sepsis and Inflammation: Description of the Various Adsorptive Techniques and their Failure to Improve Outcomes
Honoré, P. M., Blackman, S., Perriens, E., Oueslati, I., Haddad, C., Al-Sammour, C., Bendoumou, M., Ramos-Prieto, M., Vornicu, O., Dincq, A.-S., et al. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000185 · Cited by 4
Cytokine modulation in abdominal septic shock via the crucial role of IL-6 signaling in endothelial dysfunction
Ueno, T., Ikeda, T., Okihara, M., Akashi, I., Yokoyama, T., Kihara, Y., Konno, O., Nakamura, Y., Iwamoto, H., Ueno, Y., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1042487 · Cited by 4
Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis
Pandey, G., Ghosh, I., Sangha, S. S., & Srivastava, A. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24805 · Cited by 4
Multiple-Organ Extracorporeal Support Therapies in Critically Ill Patients
Daza, J. L., Ferro, M. C. C., Cárdenas, A. D., Daza, L. J., Rey, E., de Jong, J., Galindo, J., Gutiérrez, G., Puello, L., & de la Cruz, Y. (2021) · Open Journal of Nephrology · doi:10.4236/ojneph.2021.112023 · Cited by 4
Innovations in Intensive Care Nephrology
Kusirisin, P., Kaewdoungtien, P., Thanapongsatorn, P., Peerapornratana, S., & Srisawat, N. (2022) · Springer eBooks · doi:10.1007/978-3-031-11570-7_21 · Cited by 4
Hämoperfusion in Anästhesie und Intensivmedizin: Chancen, Risiken und Evidenz verschiedener Systeme
Gräfe, C., Weidhase, L., Liebchen, U., Weigand, M. A., & Scharf, C. (2023) · Die Anaesthesiologie · doi:10.1007/s00101-023-01341-w · Cited by 4
The Role of Endotoxin in Septic Shock
Hurley, J. C. (2019) · JAMA · doi:10.1001/jama.2018.20874 · Cited by 4
Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome
Faqihi, F. A., Alharthy, A. M., & Karakitsos, D. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.07.016 · Cited by 4
Hemoadsorption in septic shock – PRO
Ostermann, M., Ferrer, R., & Rimmelé, T. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07834-z · Cited by 4
Polymyxin B-immobilised fibre column treatment for acute exacerbation of idiopathic pulmonary fibrosis patients with mechanical ventilation: a nationwide observational study
Awano, N., Jo, T., Izumo, T., Inomata, M., Ito, Y., Morita, K., Matsui, H., Fushimi, K., Urushiyama, H., Nagase, T., et al. (2023) · Journal of Intensive Care · doi:10.1186/s40560-023-00693-0 · Cited by 5
The Use of Hemoadsorption in Cancer-Related Complications
Premužić, V., & Forni, L. G. (2025) · Blood Purification · doi:10.1159/000547348 · Cited by 3
Endotoxin Activity Assay-Guided Patient Selection for Polymyxin B Hemoperfusion: Lessons from the TIGRIS Trial and Future Directions
Iba, T., Okada, H., Miki, T., Mineshima, M., & Nagaoka, I. (2025) · Healthcare · doi:10.3390/healthcare13202603 · Cited by 3
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?
Papatheodosiou, D., Giamarellos‐Bourboulis, E. J., & Tsoukas, C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2646192 · Cited by 3
The bug, the burden, and the biology: beyond host-centric phenotyping in sepsis
Kitsios, G. D., & Baron, R. M. (2026) · Journal of Clinical Investigation · doi:10.1172/jci203658 · Cited by 3
Innovation in sepsis trials: rethinking endpoints, statistics and patient stratification
David, S., Léone, M., Girardis, M., Müller, M. M., Gavrilović, S., Domizi, R., Damiani, E., Martín‐Loeches, I., Ferrer, R., Bode, C., et al. (2026) · Intensive Care Medicine Experimental · doi:10.1186/s40635-026-00911-7 · Cited by 3
HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE)
Wongtirawit, N., Inyu, W., Prajantasen, U., Phairatwet, P., & Ratanarat, R. (2026) · Critical Care · doi:10.1186/s13054-026-06121-7 · Cited by 4
Granulocyte and Monocyte Adsorption Therapy in Patients With Sepsis: A Feasibility Study
Nishida, O., Nakamura, T., Nakada, T., Takahashi, G., Masuda, Y., Tsubouchi, H., Kakihana, Y., SAKAMOTO, Y., Takasu, O., Suzuki, H., et al. (2025) · Artificial Organs · doi:10.1111/aor.14943 · Cited by 3
Organ Failure, Endotoxin Activity, and Mortality in Septic Shock
Molinari, L., Tidswell, M., Al-Khafaji, A. H., Davison, D. L., Galphin, C. M., Kamaluddin, E., Foster, D., & Kellum, J. A. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001308 · Cited by 3
Self-citation
Current treatment options for sepsis based on sorption methods (review)
Евгеньевич, К. Д., Пасечник, И. Н., & Vershinina, M. G. (2019) · Laboratory Service · doi:10.17116/labs2019804122 · Cited by 3
Renal replacement and extracorporeal therapies in critical care: current and future directions
Lane, S. F., Harvey-Jones, E. J., Ward, O., & Davies, R. (2023) · Acute Medicine Journal · doi:10.52964/amja.0951 · Cited by 3
Endotoxemia Correlates with Kidney Function and Length of Stay in Critically Ill Patients
Piret, S. E., Khan, S., Fairuz, F., Gholami, S., Davis, M., Kim, C. K., Espinoza, M., Foster, D., Kellum, J. A., Ahmad, S., et al. (2023) · Blood Purification · doi:10.1159/000534107 · Cited by 3
Self-citation
Improved survival in COVID ‐19 related sepsis and ARDS treated with a unique “triple therapy” including therapeutic plasma exchange: A single center retrospective analysis
Keith, P. D., Bohn, R. I. C., Nguyen, T. C., Scott, L. K., Richmond, M., Day, M. S., Choe, C. H., Perkins, L., Burnside, R. C., Pyke, R., et al. (2024) · Journal of Clinical Apheresis · doi:10.1002/jca.22107 · Cited by 3
A systematic review of the efficacy of direct hemoperfusion with a polymyxin B–immobilized fibre column to treat rapidly progressive interstitial pneumonia
Kamiya, H., & Panlaqui, O. M. (2019) · SAGE Open Medicine · doi:10.1177/2050312119861821 · Cited by 3
Sepsis and Septic Shock
Reddi, B. A. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_17 · Cited by 3
Mortality time frame variability in septic shock clinical trials: A systematic review
Laserna, A., Cuenca, J. A., Martin, P., Fowler, C., Correa, J. E. B., Manjappachar, N. K., Fowler, C. S., Lopez-Olivo, M. A., Borges, M., Sprung, C. L., et al. (2025) · Medicina Intensiva · doi:10.1016/j.medine.2025.502172 · Cited by 4

Authors: Dellinger, R. P., Bagshaw, S. M., Antonelli, M., Foster, D. M., Klein, D. J., Marshall, J. C., Palevsky, P. M., Weisberg, L. S., Schorr, C. A., Trzeciak, S., Walker, P. M., & for the EUPHRATES Trial Investigators
Affiliations: Cooper University Hospital (US)
University of Alberta (CA)
Università Cattolica del Sacro Cuore (IT)
Spectral Medical Inc, Toronto, Canada
St. Michael's Hospital (CA)
University of Pittsburgh (US)
Corresponding author: Dellinger, R. Phillip
ORCID: Bagshaw, Sean M.
Antonelli, Massimo
Klein, David J.
Marshall, John C.
Palevsky, Paul M.
Weisberg, Lawrence S.
Schorr, Christa A.
Trzeciak, Stephen
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2018-10-09
Volume: 320
Issue: 14
Pages: 1455
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2018.14618
PMC: PMC6233793
OpenAlex: W2897735762
Cited by: 502
References: 25
Citations by year: 2026: 73 · 2025: 71 · 2024: 71 · 2023: 70 · 2022: 52 · 2021: 54 · 2020: 63 · 2019: 40 · 2018: 5
FWCI: 31.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Figshare (submittedVersion)
Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
Funders: University of Nebraska Medical Center
Memorial Sloan-Kettering Cancer Center
Cleveland Clinic
University of Pittsburgh
East Carolina University
Thomas Jefferson University
Temple University
University of Alberta
Medical Center, University of Pittsburgh
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords: polymyxin B hemoperfusion, septic shock, endotoxin activity, endotoxemia, 28-day mortality, multiple organ failure, sepsis, critically ill patients, endotoxin activity assay, survival outcomes, sepsis treatment, APACHE II score, multiple organ dysfunction score, sepsis mortality
MeSH terms: Adult, Aged, Anti-Bacterial Agents, Endotoxins, Female, Humans, Male, Middle Aged, Polymyxin B, Shock, Septic, Survival Analysis, Hospital Mortality, APACHE

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks